Page last updated: 2024-12-07
2-o-methylpyrogallol
Description
2-O-methylpyrogallol is a naturally occurring phenolic compound found in various plants, including Rhus verniciflua and Pistacia lentiscus. It exhibits antioxidant and anti-inflammatory properties. Research suggests its potential as a therapeutic agent for conditions like neurodegenerative diseases and cancer. The compound is often synthesized via methylation of pyrogallol, and its biological activity is attributed to its ability to scavenge free radicals and inhibit the production of inflammatory mediators. Studies investigating 2-O-methylpyrogallol explore its potential therapeutic applications and its role in plant defense mechanisms.'
2-O-methylpyrogallol: metabolite of gallic acid; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 121805 |
| CHEMBL ID | 485792 |
| CHEBI ID | 165231 |
| SCHEMBL ID | 69297 |
| MeSH ID | M0287842 |
Synonyms (51)
| Synonym |
|---|
| 2-methoxyresorcinol |
| 1,3-benzenediol, 2-methoxy- |
| DIVK1C_006843 |
| SDCCGMLS-0066488.P001 |
| SPECTRUM_000398 |
| SPECTRUM5_000160 |
| BSPBIO_002799 |
| NCGC00095532-01 |
| KBIO2_000878 |
| KBIOGR_002060 |
| KBIO2_003446 |
| KBIO2_006014 |
| KBIOSS_000878 |
| KBIO1_001787 |
| KBIO3_002299 |
| SPECTRUM3_001180 |
| SPECTRUM4_001560 |
| SPECTRUM2_001836 |
| SPBIO_001911 , |
| SPECPLUS_000747 |
| SPECTRUM211066 |
| NCGC00095532-02 |
| AKOS000282505 |
| CHEBI:165231 |
| 29267-67-2 |
| 2-methoxybenzene-1,3-diol |
| 2-o-methylpyrogallol |
| CHEMBL485792 |
| pyrogallol-2-methyl ether |
| 1,3-dihydroxy-2-methoxybenzene |
| 2-methoxy-1,3-benzenediol |
| CCG-38464 |
| 3uw7031f6p , |
| einecs 249-542-1 |
| unii-3uw7031f6p |
| FT-0638846 |
| resorcinol, 2-methoxy- |
| SCHEMBL69297 |
| 1,3-dihydroxy-2-methoxybenzene,2-methoxyresorcinol |
| 2-methoxy-1,3-benzenediol # |
| DTXSID60183520 |
| mfcd00017299 |
| sr-05000002376 |
| SR-05000002376-1 |
| J-017464 |
| 2-methoxyresorcino |
| BRD-K20559594-001-03-2 |
| 2,6-dihydroxyanisole |
| Q27258054 |
| CS-0450653 |
| PD002133 |
Drug Classes (2)
| Class | Description |
|---|
| phenols | Organic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring. |
| methoxybenzenes | Any aromatic ether that consists of a benzene skeleton substituted with one or more methoxy groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (1)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|
| TDP1 protein | Homo sapiens (human) | Potency | 4.1095 | 0.0008 | 11.3822 | 44.6684 | AID686979 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Bioassays (5)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6
| A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| AID977602 | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6
| Structure-based identification of OATP1B1/3 inhibitors. |
| AID977599 | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6
| Structure-based identification of OATP1B1/3 inhibitors. |
| AID377909 | Antioxidant activity assessed as DPPH free radical scavenging activity | 2000 | Journal of natural products, Oct, Volume: 63, Issue:10
| Urinary metabolites of gallic acid in rats and their radical-scavenging effects on 1,1-diphenyl-2-picrylhydrazyl radical. |
| AID1159550 | Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening | 2015 | Nature cell biology, Nov, Volume: 17, Issue:11
| 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.53
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.53 (24.57) | | Research Supply Index | 1.79 (2.92) | | Research Growth Index | 4.32 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |